Is Corcept Therapeutics (CORT) Undervalued After CHMP Backing For Relacorilant?

Corcept Therapeutics (CORT) is in focus after the European Medicines Agency’s CHMP backed approval of relacorilant with nab-paclitaxel for platinum-resistant ovarian cancer, highlighting a key licensed medicine in a substantial treatment market.

Corcept Therapeutics’ recent CHMP backing arrives after a strong run, with the share price gaining about 33% over 90 days and more than tripling year to date, while the 5-year total shareholder return above 4x signals long-term momentum, even as the 1-day move dipped slightly following the news.

Look beyond Corcept Therapeutics and compare this move with other specialists with strong fundamentals using our curated 38 healthcare AI stocks in the broader healthcare and AI-enabled drug development space.

Corcept Therapeutics now trades after a sharp rerating, and the question is whether that move reflects durable business progress or a sentiment shift around a single regulatory catalyst. It is time to see what the current valuation implies.

Most Popular Narrative: 18% Undervalued

On the most followed view of Corcept Therapeutics, a fair value of $141 sits above the last close at $116.10. This puts the spotlight on whether future execution can live up to the growth baked into that gap.

The publication of the CATALYST study and the resulting increased awareness and screening for hypercortisolism among physicians are expanding the potential addressable patient pool, which is expected to drive significant acceleration in revenue growth over the next several years.

Global demographic shifts, including an aging population with higher rates of endocrine and metabolic diseases, along with rising healthcare spend, are supporting longer-term expansion of Corcept's total addressable market, underpinning sustained topline growth.

See why 60 investors see Corcept Therapeutics as 18% undervalued.

Result: Fair Value of $141 (UNDERVALUED)

Still, the bullish Corcept Therapeutics story can unravel if Korlym faces faster generic erosion, or if relacorilant and Lifyorli hit regulatory or uptake setbacks.

Find out about the key risks to this Corcept Therapeutics narrative.

Next Steps

Whether you are confident or cautious about Corcept Therapeutics after this run and its regulatory progress, you still need to move quickly and test the thesis against the numbers yourself. To weigh both sides of the story in one place, review the 2 key rewards and 2 important warning signs.

Looking for more Corcept Therapeutics style ideas?

Do not stop with Corcept Therapeutics. Use the Simply Wall St Screener to spot other opportunities that fit your risk, income, and valuation preferences before the crowd.

• Target resilient balance sheets by reviewing the list of solid balance sheet and fundamentals (24 results) that can help anchor your portfolio when conditions turn.
• Hunt for mispriced quality through the 32 high quality undervalued stocks that filters for strong fundamentals at compressed valuations.
• Stack potential income streams using the 8 dividend fortresses that highlights companies offering yields of 5% or more.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com